40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.
Epistemonikos ID: a3f92972e2fb44dce9c2c7b1a9abc172a751b55d
First added on: Jan 10, 2026